Full Text
Abstract
Summary. The fibrinolytic system can be considered a truly unique and multicomponent structure of the human body, involved in multiple
physiological and pathological processes: cell migration/metastasis, angiogenesis, inflammation, degradation of the extracellular matrix,
and tissue remodeling. Laboratory determination of the plasmin-a2‑antiplasmin complex level as a biomarker of hyperfibrinolysis and/or
increased thrombotic risk in clinical practice is promising in diagnostic and prognostic terms. This review provides up-to-date information
on the structure, functions, diagnostic capabilities, and application of plasmin-α2‑antiplasmin complex as a marker of thrombotic danger
in clinical practice.
For citation: Tanashyan M.M., Roitman E.V., Raskurazhev A.A., Kuznetsova P.I., Mazur A.S. Thrombotic risk markers: рlasmin-α2‑antiplasmin complex.
Tromboz, gemostaz i reologiya. 2025;(3):27–39. (In Russ.).
References
1. Kwaan H.C. From fibrinolysis to the plasminogen-plasmin system
and beyond: a remarkable growth of knowledge, with personal
observations on the history of fibrinolysis. Semin Thromb Hemost.
2014;40(5):585–91. DOI: 10.1055/s‑0034‑1383545.
2. Christensen L.R., Macleod C.M. A proteolytic enzyme of serum:
characterization, activation, and reaction with inhibitors. J Gen
Physiol. 1945;28(6):559–83. DOI: 10.1085/jgp.28.6.559.
3. Macfarlane R.G., Biggs R. Fibrinolysis; its mechanism and significance. Blood. 1948;3(10):1167–87.
4. Booth N.A., Bennett B. Plasmin-alpha 2‑antiplasmin complex as
an indicator of in vivo fibrinolysis. Br J Haematol. 1982;50(3):537–
41. DOI: 10.1111/j.1365‑2141.1982.tb01950.x.
5. Voitsehovsky V.V., Landyshev Yu.S., Tseluko S.S., Zabolotskikh T.V.
Haemorrhagic syndrome in clinical practice. Blagoveshchensk:
Amurskaya gosudarstvennaya medicinskaya akademiya, 2014. 255
pp. (In Russ.).
6.Akhmedov V.A., Shadevsky V.M., Sudakova A.N. et al. Rare clinical case of Hageman disease in the patient of the cardiological
department. RMZh. 2018;6(I):46–8. (In Russ.).
7.Podorolskaya L.V., Chumakova E.L., Lobanova E.V., Alekseeva L.A.
Fibrinolytic activity of the urine in patients with arterial hypertension with different efficacy of antihypertensive treatment. Klinicheskaja nefrologija. 2010;(5):50–2. (In Russ.).
8. Wiman B., Jacobsson L., Andersson M., Mellbring G. Determination of plasmin-alpha 2‑antiplasmin complex in plasma samples by means of a radioimmunoassay. Scand J Clin Lab Invest. 1983;43(1):27–33. DOI: 10.1080/00365518309168219.
9. Cesarman-Maus G., Hajjar K.A. Molecular mechanisms of fibrinolysis. Br J Haematol. 2005;129(3):307–21. DOI: 10.1111/j.1365‑2141.2005.05444.x.
10. Miszta A., Huskens D., Donkervoort D. et al. Assessing plasmin
generation in health and disease. Int J Mol Sci. 2021;22(5):2758.
DOI: 10.3390/ijms22052758.
11. Keragala C.B., Medcalf R.L. Plasminogen: an enigmatic zymogen.
Blood. 2021;137(21):2881–9. DOI: 10.1182/blood.2020008951.
12. Zhalyalov A.S., Balandina A.N., Kuprash A.D. et al. The overview of fibrinolysis system contemporary concepts and of its disorders diagnostic methods. Voprosy gematologii/onkologii i immunopatologii v pediatrii. 2017;16(1):69–82. (In Russ.). DOI: 10.24287/1726‑1708‑2017‑16‑1‑69‑82.
13. Su S.C., Lin C.W., Yang W.E. et al. The urokinase-type plasminogen activator (uPA) system as a biomarker and therapeutic target
in human malignancies. Expert Opin Ther Targets. 2016;20(5):551–
66. DOI: 10.1517/14728222.2016.1113260.
14. Draxler D.F., Zahra S., Goncalves I. et al. Tranexamic acid rapidly
inhibits fibrinolysis, yet transiently enhances plasmin generation
in vivo. Blood Coagul Fibrinolysis. 2021;32(3):172–9. DOI: 10.1097/
MBC.0000000000001008.
15. Altalhi R., Pechlivani N., Ajjan R.A. PAI‑1 in Diabetes: pathophysi‑
ology and role as a therapeutic target. Int J Mol Sci. 2021;22(6):3170.
DOI: 10.3390/ijms22063170.
16. Zhai J., Li Z., Zhou Y., Yang X.The role of plasminogen activator
inhibitor‑1 in gynecological and obstetrical diseases: an update
review. J Reprod Immunol. 2022;150:103490. DOI: 10.1016/j.
jri.2022.103490.
17. Levine J.A., Oleaga C., Eren M. et al. Role of PAI‑1 in hepatic ste‑
atosis and dyslipidemia. Sci Rep. 2021;11(1):430. DOI: 10.1038/
s41598‑020‑79948‑x.
18. Morrow G.B., Mutch N.J. Past, present, and future perspectives of
plasminogen activator inhibitor 1 (PAI‑1). Semin Thromb Hemost.
2023;49(3):305–13. DOI: 10.1055/s‑0042‑1758791.
19. Aoki N. Discovery of alpha2‑plasmin inhibitor and its congenital
deficiency. J Thromb Haemost. 2005;3(4):623–31. DOI: 10.1111/j.153
8‑7836.2004.01055.x.
20. Wu G., Quek A.J., Caradoc-Davies T.T. et al. Structural stud‑
ies of plasmin inhibition. Biochem Soc Trans. 2019;47(2):541–57.
DOI: 10.1042/BST20180211.
21. Bokarev I.N., Melnikov A.P., Burykh S.I. TAFI phenomenon and
its clinical significance. Klinicheskaja medicina. 2023;101(11):521–4.
DOI: 10.30629/0023‑2149‑2023‑101‑11‑521‑524. (In Russ.).
22. Sillen M., Declerck P.J. Thrombin activatable fibrinolysis inhibitor
(TAFI): an updated narrative review. Int J Mol Sci. 2021;22(7):3670.
DOI: 10.3390/ijms22073670.
23. Aisina R.B., Mukhametova L.I. Structure and functions of lasminogen/plasmin system. Bioorganicheskaja himija. 2014;40(6):642–57. (In Russ.).
24. Zamolodchikova T.S., Tolpygo S.M., Kotov A.V. Serine proteases in
the functional activity of the nervous system. Vestnik Novgorodskogo gosudarstvennogo universiteta. 2023;(2):196–207. DOI: 10.34
680/2076‑8052.2023.2(131).196‑207. (In Russ.).
25. Hoirisch-Clapauch S. Mechanisms affecting brain remodeling in
depression: do all roads lead to impaired fibrinolysis? Mol Psychiatry. 2022;27(1):525–33. DOI: 10.1038/s41380‑021‑01264‑1.
26. Pala Z.R., Ernest M., Sweeney B. et al. Beyond cuts and scrapes:
plasmin in malaria and other vectorborne diseases. Trends Parasitol. 2022;38(2):147–59. DOI: 10.1016/j.pt.2021.09.008.
27. Heissig B., Salama Y., Takahashi S. et al. The multifaceted role
of plasminogen in inflammation. Cell Signal. 2020;75:109761.
DOI: 10.1016/j.cellsig.2020.109761.
28. Kaplieva I.V., Zakharchenko V.R., Frantsiyants E.M. et al. Agerelated characteristics of the content and activity of certain components of the blood fibrinolytic system in cases of uterine cancer. Sibirskij nauchnyj medicinskij zhurnal. 2024;44(4):105–12.
DOI: 10.18699/SSMJ20240411. (In Russ.).
29. Franzyants E.M., Maksimov G.K., Kozlova L.S. et al. Participation of
the kinin and fibrinolytic systems in the growth of malignant gliomas. Vestnik Juzhnogo nauchnogo centra RAN. 2011;7:103–7. (In Russ.).
30. Kit O.I., Frantsiyants E.M., Kozlova L.S. et al. Fibrinolytic system
in tumors and adjacent tissues in males with esophageal squamous cell carcinoma. Sovremennye problemy nauki i obrazovanija. 2017;(2):20. (In Russ.).
31. Hva sC.L., Larsen J.B. The fibrinolytic system and its measurement:
history, current uses and future directions for diagnosis and treatment. Int J Mol Sci. 2023;24(18):14179. DOI: 10.3390/ijms241814179.
32. Al Dieri R., de Laat B., Hemker H.C.Thrombin generation: what
have we learned? Blood Rev. 2012;26(5):197–203. DOI: 10.1016/j.
blre.2012.06.001.
33. Longstaff C. Measuring fibrinolysis: from research to routine diagnostic assays. J Thromb. Haemost. 2018;16(4):652–662. DOI: 10.1111/
jth.13957.
34. van Geffen M., LoofA., Lap P. et al. A novel hemostasis assay for the
simultaneous measurement of coagulation and fibrinolysis. Hematology. 2011;16(6):327–36. DOI: 10.1179/102453311X13085644680348.
35. Simpson M.L., Goldenberg N.A., Jacobson L.J. et al. Simultaneous
thrombin and plasmin generation capacities in normal and abnormal states of coagulation and fibrinolysis in children and adults.
Thromb Res. 2011;127(4):317–23. DOI: 10.1016/j.thromres.2010.12.011.
36. Tarandovskiy I.D., Rajabi A.A., Karnaukhova E., Buehler P.W. Contradictory to its effects on thrombin, C1‑inhibitor reduces plasmin
generation in the presence of thrombomodulin. J Thromb Thrombolysis. 2019;48(1):81–7. DOI: 10.1007/s11239‑019‑01869‑y.
37. Miszta A., Ahmadzia H.K., Luban N.L.C. et al. Application of
a plasmin generation assay to define pharmacodynamic effects of
tranexamic acid in women undergoing cesarean delivery. J Thromb
Haemost. 2020;19(1):221–32. DOI: 10.1111/jth.15114.
38. Zhang L., ChenY., HuR. et al. A single-center study of reference
intervals for TAT, PIC, TM and t-PAIC in healthy older Chinese
adults. Thromb J. 2024;22(1):82. DOI: 10.1186/s12959‑024‑00651‑2.
39. Nekrasova L.A., Nesterova O.Yu., Samokhodskaya L.M. et al. Relationship of fibrinolysis system proteins with severity of COVID‑19.
A review of current clinical data and promising therapeutic
strategies. Kardiologicheskij vestnik. 2022;17(3):29–38. (In Russ.).
DOI: 10.17116/Cardiobulletin20221703129.
40. Boknäs N., Laine C., Hillarp A. et al. Associations between hemostatic markers and mortality in COVID‑19 — compounding
effects of D-dimer, antithrombin and PAP complex. Thromb Res.
2022;213:97–104. DOI: 10.1016/j.thromres.2022.03.013.
41. Li Y., Li H., Wang Y. et al. Potential biomarkers for early diag‑
nosis, evaluation, and prognosis of sepsis-induced coagulopathy. Clin Appl Thromb Hemost. 2023;29:10760296231195089.
DOI: 10.1177/10760296231195089.
42. Wada T., Gando S. Phenotypes of disseminated intravascular
coagulation. Thromb Haemost. 2024;124(3):181–91. DOI: 10.1055/
a‑2165‑1142.
43. Takahashi H., Hanano M., Takizawa S. et al. Plasmin-alpha
2‑plasmin inhibitor complex in plasma of patients with disseminated intravascular coagulation. Am J Hematol. 1988;28(3):162–6.
DOI: 10.1002/ajh.2830280306.
44. Fukuda C., Iijima K., Nakamura K.Clinical usefulness of the measurements of plasmin-alpha 2‑plasmin inhibitor complex and
plasma tissue factor activity in patients with disseminated intra‑
vascular coagulation. Rinsho Byori. 1996;44(8):750–6. (In Japanese).
45. Park K.J., Kim H.J., Hwang S.C. et al. The imbalance between coagulation and fibrinolysis is related to the severity of the illness
and the prognosis in sepsis. Korean J Intern Med. 1999;14(2):72–7.
DOI: 10.3904/kjim.1999.14.2.72.
46. Yoshinobu S., Honda G., Kawano N. et al. Clinical features of dis‑
seminated intravascular coagulation according to the French-American-British classification in patients with acute leukemia
and thrombomodulin alfa treatment — a cohort study usinga postmarketing surveillance database. Clin Appl Thromb Hemost.
2021;27:10760296211054094. DOI: 10.1177/10760296211054094.
47. ZheniloV.M., Konstantinova G.A., Bychkov A.A. Study of hemostasis system while the operative treatment of malignant tumors of prostate and bladder. Vladikavkazskij mediko-biologicheskij vestnik. 2011;13(20–21):6–30. (In Russ.).
48. Nijziel M.R., Van Oerle R., Hellenbrand D. et al. The prognostic value of the soluble urokinase-type plasminogen activator receptor (s-uPAR) in plasma of breast cancer patients with and
without metastatic disease. J Thromb Haemost. 2003;1(5):982–6.
DOI: 10.1046/j.1538‑7836.2003.00207.x.
49. Ercan H., Mauracher L.M., Grilz E. et al. Alterations of the platelet
proteome in lung cancer: accelerated F13A1 and ER processing as
new actors in hypercoagulability. Cancers (Basel). 2021;13(9):2260.
DOI: 10.3390/cancers13092260.
50. Cheng Y., Liu J., Su Y. et al. Clinical impact of coagulation and fibrinolysis markers for predicting postoperative venous thromboembolism in total joint arthroplasty patients. Clin Appl Thromb Hemost. 2019;25:1076029619877458. DOI: 10.1177/1076029619877458.
51. Guo X., Tao H., Li D., LiY.The α2‑plasmin inhibitor-plasmin complex is a potential biomarker of venous thromboembolism in orthopedic trauma patients. Clin Lab. 2021;67(4). DOI: 10.7754/Clin.
Lab.2020.200856.
52. Lin Z., Sun H., Li D. et al. Thrombin antithrombin complex concentration as an early predictor of deep vein thrombosis after total
hip arthroplasty and total knee arthroplasty. BMC Musculoskelet
Disord. 2022;23(1):574. DOI: 10.1186/s12891‑022‑05532‑1.
53. Reda S., Schwarz N., Müller J. et al. Fibrinolysis biomarker, thrombin, and activated protein C level alterations after coagulation
activation depend on type of thrombophilia and clinical phenotype. Res Pract Thromb Haemost. 2024;8(2):102351. DOI: 10.1016/j.
rpth.2024.102351.
54. Liu J., Wang F., Wang Y. et al. Diagnostic value of plasmin-α2‑plasmin inhibitor complex in patients with malignant tumor and venous thromboembolism. Hippokratia. 2023;27(2):37–40.
55. Liang H., Guo X., Li Y. Cervical cancer associated biomarkers of
identify high risk of venous thrombosis. Clin Lab. 2020;66(5).
DOI: 10.7754/Clin.Lab.2019.190905.
56. Li L., Gao L., Wu X. et al. Changes in biomarkers of coagulation, fibrinolytic, and endothelial functions for evaluating the predisposition
to venous thromboembolism in patients with hereditary throm‑
bophilia. Clin Appl Thromb Hemost. 2020;26:1076029620944471.
DOI: 10.1177/1076029620944471.
57. Ikeda M., Kan-no H., Hayashi M. et al. Predicting perioperative
venous thromboembolism in Japanese gynecological patients. PLoS
One. 2014;9(2):e89206. DOI: 10.1371/journal.pone.0089206.
58. Cushman M., Larson J.C., Rosendaal F.R. et al. Biomarkers, meno‑
pausal hormone therapy and risk of venous thrombosis: the Women’s Health Initiative. Res Pract Thromb Haemost. 2018;2(2):310–9.
DOI: 10.1002/rth2.12100.
59. Evensen L.H., Folsom A.R., Pankow J.S. et al. Hemostatic factors,
inflammatory markers, and risk of incident venous thromboembolism: the multi-ethnic study of atherosclerosis. J Thromb Haemost. 2021;19(7):1718–28. DOI: 10.1111/jth.15315.
60. Takahashi R., Ono K., Ikeda T. et al. Coagulation and fibrinolysis abnormalities in familial amyloid polyneuropathy. Amyloid.
2012;19(3):129–32. DOI: 10.3109/13506129.2012.691918.
61. Moritoyo T., Nishimura N., Hasegawa K. et al. A first-in-human
study of the anti-inflammatory profibrinolytic TMS‑007, an SMTP
family triprenyl phenol. Br J Clin Pharmacol. 2023;89(6):1809–19.
DOI: 10.1111/bcp.15651.
62. Niizuma K., Nishimura N., Hasegawa K. et al. Anti-inflammatory thrombolytic JX10 (TMS‑007) in late presentation of acute ischemic stroke. Stroke. 2024;55(12):2786–94. DOI: 10.1161/STROKEAHA.124.048464.
63. Harrington L.B., Ehlert A.N., Thacker E.L. et al. Hemostatic factor levels and cognitive decline in older adults: the cardiovascular health sStudy. J Thromb Haemost. 2021;19(5):1219–27. DOI: 10.1111/
jth.15300.
64. Sharma A., Müller J., Schuetze K. et al. Comprehensive profiling
of blood coagulation and fibrinolysis marker reveals elevated
plasmin-antiplasmin complexes in Parkinson’s disease. Biology
(Basel). 2021;10(8):716. DOI: 10.3390/biology10080716.
65. Yagi K., TaoY., Hara K. et al. Increased plasma plasmin-α2‑plasmin
inhibitor complex levels correlate with postoperative rebleeding after endoscopic surgery for spontaneous intracerebral hemorrhage. Acta Neurochir (Wien). 2020;162(12):3129–36. DOI: 10.1007/s00701‑019‑04154‑2.
66. Ostovaneh M.R., Hughes T.M., Wu C.O. et al. Deep phenotyping of
dementia in a multi-ethnic cardiovascular cohort: the multi-ethnic
study of atherosclerosis (MESA). PLoS One. 2024;19(4):e0298952.
DOI: 10.1371/journal.pone.0298952.
67. Kaminski T.W., Pawlak K., Karbowska M. et al. Association between
uremic toxin-anthranilic acid and fibrinolytic system activity in
predialysis patients at different stages of chronic kidney disease.
Int Urol Nephrol. 2018;50(1):127–35. DOI: 10.1007/s11255‑017‑1729‑1.
68. Dubin R., Cushman M., Folsom A.R. et al. Kidney function and
multiple hemostatic markers: cross sectional associations in the
multi-ethnic study of atherosclerosis. BMC Nephrol. 2011;12:3.
DOI: 10.1186/1471‑2369‑12‑3.
69. Zanetto A., Rinder H.M., Campello E. et al. Acute kidney injury
in decompensated cirrhosis is associated with both hypo-coagulable and hyper-coagulable features. Hepatology. 2020;72(4):1327–
40. DOI: 10.1002/hep.31443.
70. Shlipak M.G., Fried L.F., CrumpC. et al. Elevations of inflammatory and procoagulant biomarkers in elderly persons with renal insufficiency. Circulation. 2003;107(1):87–92. DOI: 10.1161/01.cir.0000042700.48769.59.
71. Bronisz M., Rość D., Bronisz A. et al. The role of intrinsic fibrinolytic system activation in pathogenesis of hemostasis disturbances in hemodialyzed patients with chronic renal failure. Ren Fail. 2004;26(3):223–9. DOI: 10.1081/jdi‑120039519.
72. Kanno Y., Miyashita M., Seishima M., Matsuo O. α2AP is associated
with the development of lupus nephritis through the regulation of
plasmin inhibition and inflammatory responses. Immun Inflamm
Dis. 2020;8(3):267–78. DOI: 10.1002/iid3.302.
73. Sakurai S., Kato H., Yoshida Y. et al. Profiles of coagulation and fibrinolysis activation-associated molecular markers of atypical hemolytic uremic syndrome in the acute phase. J Atheroscler Thromb.
2020;27(4):353–62. DOI: 10.5551/jat.49494.
74. Pawlak K., Ulazka B., Mysliwiec M., Pawlak D.Vascular endothelial growth factor and uPA/suPAR system in early and advanced
chronic kidney disease patients: a new link between angiogenesis and hyperfibrinolysis? Transl Res. 2012;160(5):346–54.
DOI: 10.1016/j.trsl.2012.04.004. DOI: 10.5114/aoms.2016.58929.
75. Saigusa R., AsanoY., Nakamura K. et al. Plasma plasmin-α2‑plasmin
inhibitor complex levels may predict the effect of cyclophospha‑
mide for systemic sclerosis-related interstitial lung disease. Mod
Rheumatol. 2017;27(4):618–22. DOI: 10.1080/14397595.2016.1226472.
76. Jinnin M., Ihn H., Yamane K. et al. Plasma plasmin-alpha2‑plasmin
inhibitor complex levels are increased in systemic sclerosis patients with pulmonary hypertension. Rheumatology (Oxford). 2003;42(2):240–3. DOI: 10.1093/rheumatology/keg071.
77. Shimazaki C., MatsuiMaegawa S., KimotoMatsumura Y. et al.
The serum level of plasmin-alpha2 plasmin inhibitor complex
(PIC) is useful for differentiating cardiac light chain amyloidosis
from transthyretin amyloidosis. Br J Haematol. 2023;202(6):1209–
12. DOI: 10.1111/bjh.18976.
78. Liao C., Liu G., Li L. et al. Predictive value of thrombinantithrombin
III complex and tissue plasminogen activator-inhibitor complex
biomarkers in assessing the severity of earlystage acute pancre‑
atitis. J Gastroenterol Hepatol. 2024;39(10):2088–96. DOI: 10.1111/jgh.16641.
79. Pusateri A.E., Moffatt L.T., Ho D.H. et al. Fibrinolytic dysfunction
and endotheliopathy after major thermal injury: considerations needed for new approaches to burn shock resuscitation. Shock. 2025;63(1):11–8. DOI: 10.1097/SHK.0000000000002473.
80.Chuchalin A.G., TseimakhI. Ya., Momot A.P. et al. Thrombogenic risk factors in patients with exacerbation of chronic obstructive pulmonary disease. Klinicheskaya medicina. 2015;93(12):18–23. (In Russ.).
81. Urbonavicius S., Urbonaviciene G., Honoré B. et al. Potential circulating biomarkers for abdominal aortic aneurysm expansion
and rupture — a systematic review. Eur J Vasc Endovasc Surg.
2008;36(3):273–80. DOI: 10.1016/j.ejvs.2008.05.009.
82. Doyle A.J., Retter A., Parmar K. et al. Temporal changes in markers of coagulation and fibrinolysis in adults during extracorporeal membrane oxygenation. Perfusion. 2024;25:2676591241267218.
DOI: 10.1177/02676591241267218.
83. Helms J., Curtiaud A., Severac F. et al. Fibrinolysis as a causative mechanism for bleeding complications on extracorporeal membrane oxygenation: a pilot observational prospective study. Anesthesiology. 2024;141(1):75–86. DOI: 10.1097/ALN.0000000000004980.
84. Yingqun C., Zihan Y., Junshi W. et al. The value of thrombus markers applied in patients with respiratory failure. J Med Biochem.
2024;44(1):31–45. DOI: 10.5937/jomb0‑50697.
85. Dujardin R.W.G., Kleinveld D.J.B., van den Brom C.E. et al. Older
females have increased mortality after trauma as compared with
younger females and males, associated with increased fibrinolysis. J Trauma Acute Care Surg. 2024;96(5):831–7. DOI: 10.1097/
TA.0000000000004235.
86. de Lloyd L., Jenkins P.V., Bell S.F. et al. Acute obstetric coagulopathy during postpartum hemorrhage is caused by hyperfibrinolysis and dysfibrinogenemia: an observational cohort study. J Thromb Haemost. 2023;21(4):862–79. DOI: 10.1016/j.jtha.2022.11.036.
87. Keragala C.B., McFadyen J.D., Ho H. et al. Plasma from patients
with vaccineinduced immune thrombotic thrombocytopenia displays increased fibrinolytic potential and enhances tissue-type plasminogen activator but not urokinase-mediated plasminogen activation. J Thromb Haemost. 2024;22(3):785–93. DOI: 10.1016/j.jtha.2023.10.027.
88. Deanda A.Jr., Spiess B.D. Aprotinin revisited. J Thorac Cardiovasc
Surg. 2012;144(5):998–1002. DOI: 10.1016/j.jtcvs.2012.06.035.
89. Lam T., Medcalf R.L., Cloud G.C. et al. Tranexamic acid for haemostasis and beyond: does dose matter? Thromb J. 2023;21(1):94.
DOI: 10.1186/s12959‑023‑00540‑0.
90. Mergoum A.M., Mergoum A.S., Larson N.J. et al. Tranexamic
acid use in the surgical arena: a narrative review. J Surg Res.
2024;302:208–21. DOI: 10.1016/j.jss.2024.07.042.
91. Medcalf R.L., Davis S.M. Plasminogen activation and thrombolysis
for ischemic stroke. Int J Stroke. 2012;7(5):419–25. DOI: 10.1111/j.17
47‑4949.2012.00783.x.
92. Guillermin A., Yan D.J., Perrier A., Marti C. Safety and efficacy of
tenecteplase versus alteplase in acute coronary syndrome: a systematic review and meta-analysis of randomized trials. Arch Med
Sci. 2016;12(6):1181–7. DOI: 10.5114/aoms.2016.58929.
93. Palaiodimou L., Katsanos A.H., Turc G. et al. Tenecteplase vs
alteplase in acute ischemic stroke within 4.5 hours: a systematic review and meta-analysis of randomized trials. Neurology.
2024;103(9): e209903. DOI: 10.1212/WNL.0000000000209903.
94. Lin H., Xu L., Yu S. et al. Therapeutics targeting the fibrinolytic system. Exp Mol Med. 2020;52(3):367–79. DOI: 10.1038/s12276‑020‑0397‑x.
95. Hennan J.K., Morgan G.A., Swillo R.E. et al. Effect of tiplaxtinin
(PAI‑039), an orally bioavailable PAI‑1 antagonist, in a rat model of
thrombosis. J Thromb Haemost. 2008;6(9):1558–64. DOI: 10.1111/j.1
538‑7836.2008.03063.x.
96. Kuş C., Özer E., Korkmaz Y. et al. Benzamide and benzamidine compounds as new inhibitors of urokinasetype plasminogen activators. Mini Reviews in Medicinal Chemistry. 2018;18(20):1753–8. DOI:
10.2174/138955751866618081611074